Basel, 02 March 2010
Roche Annual General Meeting: dividend raised by 20%
23rd consecutive dividend increase
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 698 shareholders in attendance, representing 143,055,648, or 89.4% of a total of 160,000,000 bearer shares, approved the 2009 Annual Report and financial statements. They also authorised a +20% increase in the dividend to 6.00 Swiss francs per share and non-voting equity. With this increase, the payout ratio rises to 53%, which means that about half of net income will be paid out to shareholders.
Shareholders once again took part in a consultative vote on Roche’s Remuneration Report. The report was approved with 99% of the votes represented.
DeAnne Julius and Beatrice Weder di Mauro were re-elected to the Board for another three-year term. William M. Burns and Arthur D. Levinson were elected as new members of the Board. Peter Brabeck and Horst Teltschik did not stand for re-election to the Board.
Franz B. Humer, Chairman of the Board of Directors, said: “We are grateful to Peter Brabeck and Horst Teltschik for their exceedingly valuable contributions as Board members over the years. With the successful completion of the Genentech transaction and a consistent focus on our two core businesses – Pharmaceuticals and Diagnostics – Roche is extremely well placed for the future.”
Severin Schwan said: “I’m delighted that we’ve been able to complete the integration of Genentech rapidly and successfully. We further strengthened our market position in 2009 and are off to a good start this year. Roche has one of the strongest product pipelines in the industry, and we will continue to rely on scientific and research excellence in the future.”
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned are protected by law.